WO1997038646A2 - Materiels orthopediques - Google Patents

Materiels orthopediques Download PDF

Info

Publication number
WO1997038646A2
WO1997038646A2 PCT/GB1997/001066 GB9701066W WO9738646A2 WO 1997038646 A2 WO1997038646 A2 WO 1997038646A2 GB 9701066 W GB9701066 W GB 9701066W WO 9738646 A2 WO9738646 A2 WO 9738646A2
Authority
WO
WIPO (PCT)
Prior art keywords
prepolymer
catalyst
fluoride
bandage according
bandage
Prior art date
Application number
PCT/GB1997/001066
Other languages
English (en)
Other versions
WO1997038646A3 (fr
Inventor
Kevin Andrew Yeomans
Peter John West
Claire Peel
Michael Francis Shelvey
Peter Hubert Bentley
Original Assignee
Smith & Nephew Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608004.9A external-priority patent/GB9608004D0/en
Priority claimed from GBGB9615129.5A external-priority patent/GB9615129D0/en
Priority claimed from GBGB9704641.1A external-priority patent/GB9704641D0/en
Application filed by Smith & Nephew Plc filed Critical Smith & Nephew Plc
Priority to AU25726/97A priority Critical patent/AU2572697A/en
Priority to EP97917345A priority patent/EP0847282A1/fr
Publication of WO1997038646A2 publication Critical patent/WO1997038646A2/fr
Publication of WO1997038646A3 publication Critical patent/WO1997038646A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/07—Stiffening bandages
    • A61L15/12—Stiffening bandages containing macromolecular materials

Definitions

  • This invention relates to orthopaedic casting and splinting bandages.
  • this invention relates to orthopaedic casting and splinting materials based on synthetic resins which, upon contact with water, will cross-link and harden to form a weight bearing support for a limb or body portion and to such resins which on contact with water will cross-link and harden.
  • Resin based splinting and casting materials find wide use in the immobilisation of limbs, for example the fixation of fractured bones, immobilisation of injured joints and for the support of ligaments and muscies where it is necessary to encase the limb in a partially or completely surrounding rigid form or cast.
  • a suitable material should be easily handleable, with a reasonable setting time to allow sufficient time in the case of casting bandages to mould the bandage about the limb and it should be flexible and free of offensive chemicals which may affect the patient or practitioner applying the material.
  • Splinting and casting materials comprising water activated synthetic polymers in which a cross-linkable prepolymer resin system is coated onto a suitable substrate are well known.
  • the most favoured and commercially developed systems are those based on prepoiymers which contain isocyanate functional groups and which in the presence of cold water will cross-link to form urea ⁇ bridges.
  • the resin systems usually also contain a catalyst to speed up the cross-linking reaction and so that a weight bearing cast may be formed in as short a time as possible consistent with requirements for moulding and shaping the splint.
  • the isocyanate linking reaction is usually an exothermic reaction. In meeting the working requirements for such resin systems the resin chemistry has to be carefully controlled so as to allow the resins to cure in a period of time which is acceptably short and yet not cure under conditions in which so much heat is evolved that the applied cast is uncomfortable to the wearer.
  • the present invention seeks to provide an improved orthopaedic casting bandage with a resin system which overcomes the above mentioned disadvantages
  • alkoxysiiane groups as the water activated reactive hydrolysable groups, more specifically the use of methoxysilane as the hydrolysable group has been proposed in the art.
  • the methoxysilane group has the advantage of being highly reactive with water without the need for catalysis, whereas higher molecular weight alkoxy substituents attached to the silane such as ethoxysilane or propoxysilane react more slowly and are not suitable for uncatalysed splinting and casting materials.
  • Methanol is a toxin in man, with potential to cause serious irreversible effects to the liver, central nervous systems and visual centres. It is a volatile compound, and thus patients and more possibly, plaster technicians could be exposed via inhalation as well as skin contact following its release from a setting casting material. The rate of metabolism and excretion of methanol is very low in man and thus repeated exposure to methanol may be regarded as having a cumulative effect.
  • Organo-oxy silanes are suitably defined as a group including alkoxysilanes [-Si-O-R] and acyloxysi lanes (-Si-O-C(O)-R], where R is an alkyl group aptly containing up to 10 carbon atoms.
  • Organo- oxy silane groups cross-link in the presence of water to form siloxane [-Si-O-Si] links.
  • an object of the invention is to provide a casting system which does not suffer from the aforementioned disadvantages.
  • an orthopaedic casting bandage comprising a flexible substrate, a water curable organo-oxy silane functionalised prepolymer system and a catalyst component characterised in that said catalyst component comprises a water soluble halide salt.
  • an orthopaedic casting bandage comprising a flexible substrate, a water curable organo-oxy silane functionalised prepolymer system and a catalyst component, characterised in that said catalyst comprises a water soluble alkali metal hahde salt.
  • the catalyst of the present invention comprises a water soluble halide salt.
  • Suitable water soluble halide salts include but are not limited to soluble alkali metal halide salts.
  • Apt examples of metal salts include sodium, potassium, iron, copper and zinc salts because of their low costs.
  • the catalyst of the present invention may further comprise a water soluble fluoride salt.
  • salts we include organic and inorganic halide salts.
  • Suitable halide salts include quaternary ammonium salts and alkali metal salts amongst others.
  • halides include but are not limited to the group comprising: caesium fluoride, sodium fluoride, potassium fluoride, potassium (hexa) fluoride zirconate, potassium (hexa) fluoride titanate, manganese (II) fluoride, zinc (II) fluoride, iron (III) fluoride, iron (II) fluoride, tin (II) fluoride, tetrabutylammonium fluoride, potassium chloride, ammonium chloride and acetyl chloride.
  • the catalysts are potassium fluoride, sodium fluoride and caesium fluoride.
  • the catalyst may be mixed into the organo-oxy silane functionalised prepolymer before reaction with water or may be added to the water used to react with the prepolymer.
  • Suitable amounts of catalyst when mixed in with the prepolymer are 0.01 % w/w to 10.0% w/w more suitably 0.1% to 5.0% w/w.
  • Suitable amounts of catalyst when added to water to make a solution are solutions of 0.01% to 10.0%, more suitably a 0.1% to 5.0% solution.
  • the catalyst may be present as a single chemical species or a mixture.
  • the catalyst is dispersed in the curable prepolymer of the invention using methods known to those skilled in the art.
  • a problem often associated with the use of water soluble catalysts is where the shelf life of the curable prepolymer system is reduced due to the increased reactivity of the functionalised prepolymer with atmospheric moisture in the presence of such a catalyst. This may be avoided by coating the catalyst with a coating that is insoluble in atmospheric moisture and is soluble in water, or water pervious once the. coating is hydrated.
  • a preferred feature of the present invention although not essential is the pre-treatment of the selected water soluble halide catalyst with a hydrophilic coating, before dispersion in the prepolymer. This reduces the risk of ageing of the prepolymer system.
  • the hydrophilic coating may be any suitable coating that will dissolve on contact with water or become hydrated with water such that the hydrated coating becomes water pervious, for example polyvinyl alcohol (PVA) or polyhydroxyethylmethacrylate (poly HEMA).
  • PVA polyvinyl alcohol
  • poly HEMA polyhydroxyethylmethacrylate
  • the catalysts of the present invention may be suitable for a wide range of organo-oxy silane functionalised prepoiymers.
  • the catalyst component as herein before described may additionally comprise a second catalyst component.
  • the use of a second catalyst component may benefit the curing speed of the prepolymer system.
  • the second catalyst component may be any catalyst that enhances the catalytic activity of the catalyst component of the present invention. Apt examples are hereinafter described.
  • Aptly equal amounts of the catalysts are added to the resin system, for example 1.0%, 1.25%, 2% or 2.5% of each of the first and second catalyst by weight of the prepolymer system may be added.
  • Reactive tertiary amine catalysts have been proposed for use in casting bandages, however such a use is accompanied by the possibility the catalyst may leach out or evaporate from the prepolymer system during curing or after curing.
  • Such amines may have a strong odour and the potential inhalation and absorption toxicity of tertiary amines is well known.
  • covalently bound-in is meant a catalyst that is covalently bound to the organo-oxy silane functionalised prepolymer.
  • an orthopaedic casting bandage as herein before described additionally comprising a second catalyst wherein said second catalyst is covalently bound-in.
  • the bound-in tertiary amine catalyst may be present at any appropriate location in the prepolymer.
  • they may be introduced at an end of the prepolymer molecules via a capping reaction, they may be present on a side chain extending from the main polymer backbone, or may oe part of the polymer backbone itself.
  • the tertiary amine catalyst may be optionally substituted with substituents which do not substantially adversely affect the reaction 8 of the tertiary amine catalyst with the prepolymer or the catalytic effect of the tertiary amine catalyst when present in the functionalised prepolymer system of the present invention.
  • Appropriate tertiary amine catalysts for reacting with so as to form the prepoiymers of the present invention may include but are not limited to molecules with at least two functional secondary amine groups and/or at least one functional primary amine group, for example:
  • the chemically bound-in tertiary amine catalysts may comprise a single species or mixture of species.
  • the second catalyst component may suitably comprise other water soluble metal salts.
  • examples include but are not limited to copper salts for example copper II sulphate.
  • the catalyst component of the present invention may be suitable for a wide range of organo-oxy silane functionalised prepoiymers.
  • the prepoiymers employed in the present invention may be end capped with a an organo-oxy hydrolysable group as hereinafter described. Further, the prepoiymers may comprise pendant organo- oxy hydrolysable groups.
  • Favoured end capping groups have the general formula -Si(OR) radical, -Si(OCOR) n , -Si-0-Si(OR) n , -Si-O-Si(R ⁇ ) 3 .
  • n (OR) n ⁇ Si(OC(R 3 ) C(R ⁇ )(R 2 )n, where n has a value of 1 to 3 and each of R, R 1f R 2 .
  • R 3 may be the same or different and are alkyl groups aptly containing up to 10 carbon atoms.
  • the hydrolysable alkoxy or acyloxy group is a C 2 - C 6 hydrocarbon group. More preferably the hydrolysable group is a C 2 - C ⁇ hydrocarbon alkoxy group and most preferably the hydrolysable group is an ethoxysilyl or propoxysilyl group.
  • the prepoiymers used in the invention may be precured by the addition of water to cross-link a small percentage of the available organo-oxy silane groups.
  • the advantage gained would be an increase in molecular weight, leading to an increase in viscosity.
  • organo-oxy silane functionalised prepoiymers examples include organo-oxy silane functionalised polyurethanes, one component organo-oxy silane functionalised prepoiymers made by nucleophilic addition reactions and organo-oxy silane functionalised ionic based prepoiymers.
  • organo-oxy silane functionalised prepoiymers may be prepared by for example the reaction of nucleophiles with activated carbon-carbon based moieties or Michael-type reactions, where a least one of the reagents is terminated with a hydrolysable organo-oxy silane group.
  • Patent Application PCT/GB96/00231 is incorporated herein by reference.
  • Michael - type reactions may be defined as the reaction of a nucleophile with an ⁇ , ⁇ -unsaturated carbonyl moiety.
  • Michael - type reactions may be exemplified by the reaction of acrylate or acrylamide reagents with reagents terminated with -SH, -NH 2 , -NHNH 2 , or >NH moieties.
  • Preferred Michael - type reactions include the reactions of methacrylates, bisphenol A ethoxylate diacrylates, methylene bisacrylamides, bisacrylamide or diacrylate oligomers with amine functionalised oligomers such as aminoalkyl silanes.
  • Apt nucleophilic reactions also comprise the reaction of nucleophiles with carbon-carbon based moieties, which are activated by ring strain or electron withdrawing effects. These include the reaction of reagents terminated with three membered heterocycles with reagents terminated with -SH, -NH 2 , -NH-NH 2 , >N ⁇ moieties where at least one of the reagents is further terminated with hydrolysable organo-oxy silane group.
  • Suitable reactions include the reaction of organo-oxy terminated aminoalkylenesilanes with reagents terminated with three membered heterocycles such as epoxides or aziridines.
  • Hydrolysable organo-oxy silane functionalised ionic based prepoiymers are a single component system where the group bearing the hydrolysable organo-oxy silane group is ionically bound to the prepolymer, rather than covalently bound to the prepolymer.
  • the ionic based prepoiymers may suitably be made by for example the reaction of alkyl carboxylic acids with alkyl amines, where one or both of the reagents is terminated by a water hydrolysable organo-oxy silane group, to produce a salt complex, where a salt complex is defined as a prepolymer containing ionic linkages.
  • ionic based prepoiymers The advantage conferred by ionic based prepoiymers is that the wetting out characteristics of the prepolymer are improved.
  • Wetting out is defined as the ability of the prepolymer to take up water which in turn affects the rate at which the functionalised prepoiymers react with water.
  • Hydrolysable organo-oxy silane functionalised prepoiymers where the prepolymer carries pendant hydrolysable organo-oxy groups and is terminated with reactive amines may be further modified with an acid such as acid chlorides or acid anhydrides, for example, acetyl chloride.
  • Acetyl chloride reacts with the terminating reactive amine groups liberating hydrogen chloride as a by-product, thereby producing an acidic environment which enhances the rate of the hydrolysis reaction, as herein before described.
  • the preferred prepolymer systems are free of isocyanate moieties and thus perceived health hazards associated therewith are avoided.
  • Preferred formulations of the prepolymer system may include a variety of additives conventional in the art. These additives may comprise fillers, pigments, fragrances, surfactants, lubricants or mixtures thereof.
  • Suitable powdered fillers include talc, calcium carbonate, fumed silica sold under the trade name Cab-o-SilTM, alumina and fibrous reinforcing fillers such as wollastonites (calcium metasilicate), to impart desirable viscosity and handling characteristics.
  • the fillers may be present as single chemical species or as mixtures and, when used, are aptly present in an amount of up to 50% w/w, preferably up to 20% w/w and aptly at least 1.0% w/w of the resin.
  • the prepolymer system used for casting bandages according to the invention may be carried on any substrate suitable for a casting, splinting or bracing material.
  • the prepolymer system may be coated, laminated, sprayed or impregnated onto a suitable substrate using conventional methods in the art.
  • the casting materials of the invention are prepared by nip-coating the prepolymer on to the substrate.
  • a preferred substrate is a flexible fabric carrier which may be a woven, knitted or non woven fabric which can carry enough of the prepolymer to ensure that the resultant cast has adequate strength.
  • the substrate should be sufficiently porous to allow water to come into contact with the carried prepolymer when the formed bandage is immersed in water.
  • the substrate may be in the form of tapes, bandages, sheets or other conventional forms, apt for preparing orthopaedic casting bandages, splinting materials or braces.
  • Suitable materials for forming the substrate include polyester, nylon, polypropylene, polyamides, polyolefins and glass fibre or mixtures thereof. Examples of such substrates are disclosed in Patent Nos. US 4,427,002, US 4,627,424 and EP 326, 285.
  • the substrate may be a mesh having openings through it to enable the water to penetrate into the rolled bandage to contact all of the prepolymer.
  • the openings will also permit circulation of air to and evaporation of moisture from the skin beneath the cured cast.
  • the mesh is of a loose weave or knit so as to allow at least partial impregnation as well as coating by the prepolymer.
  • the amount of prepolymer carried by the substrate before curing may vary depending on the intrinsic properties of the prepolymer and shoutd be sufficient to ensure that the resultant cast has adequate strength.
  • Suitable amounts range from 30 to 70% w/w which is calculated using the equation:
  • a hardened cast may be formed by wetting and shaping the wet material around a body member or part thereof and allowing the material to cure.
  • Aptly wetting is achieved by immersing the material in water, and removing any excess water, for example, by squeezing the material several times before application to the body member.
  • the material When removed from the water the material can be readily wrapped about a limb wherein the conventional underlying stockinette or padding is employed.
  • An alternative method for forming a cast or splint comprises applying the material to the body member followed by spraying the material with water.
  • the water used to wet the material may contain the catalyst, forming a solution as herein before described.
  • the curing reaction of the prepolymer should be sufficiently slow to allow the material to be positioned and shaped before the material becomes unworkable. Suitable working times are aptly 1 to 6 minutes more aptly 2 minutes to 4 minutes.
  • the curing reaction of the prepolymer should, however, be sufficiently fast to permit the formed cast or splint to become supportive and load-bearing as soon as possible after completion of working. Aptly the material will set and become supportive between 5 and 30 minutes, more aptly within 15 minutes and particularly in the case of a cast, will aptly become load-bearing within 60 minutes, more aptly after 10 minutes.
  • the prepoiymers employed in the present invention possess the advantage that no methanol is generated during the curing reaction, and the further advantage in that the curing reaction is only slightly exothermic thus causing no harm or discomfort to the patient.
  • the cast may be readily removed by conventional means such as by cutting with a conventional vibrating sawtooth disc.
  • the orthopaedic casting material should be protected during storage from water and moisture vapour to prevent a premature setting taking place.
  • the material can be conventionally packaged in heat sealed pouches such as metal foil polyethylene laminate pouches.
  • Example 1 Methylenebisacrylamide (109.3g, 0.71 mol) and
  • 3-aminopropyltriethoxysilane (228.6g, 1.03 mot) were placed in a 1 litre resin flask fitted with an overhead air stirrer, a thermometer and a calcium chloride guard tube.
  • the mixture was stirred at room temperature for 30 minutes before raising the temperature to 70°C, which was maintained for 48-72 hours, before cooling.
  • the prepolymer prepared above was used for the following preparations:
  • the prepolymer was coated onto a dry glass fibre bandage by passing the substrate through the prepolymer followed by passing the coated bandage through a nip roller, adjusted to a suitable pressure for obtaining a coating weight of 50-60% w/w.
  • the prepolymer was set of by dipping the coated bandage in cold water and squeezing several times before application to a mandrel representing a limb.
  • Example 2 • Methylenebisacrylamide (107.8g, 07 mol) and 3- amtnopropylt ⁇ ethoxysilane (221.4g, 1.0 mol) were placed in a 1 litre resin flask fitted with an overhead air stirrer, a thermometer and a calcium chloride guard tube
  • the prepolymer prepared above was used for the following preparation:
  • the prepolymer was set of by dipping the coated bandage in cold water and squeezing several times before application to a mandrel representing a limb
  • the prepolymer prepared above was coated onto a dry glass fibre bandage by passing the substrate through the prepolymer followed by passing the coated bandage through a nip roller, adjusted to a suitable pressure for obtaining a coating weight of 50- 60% w/w.
  • the prepolymer was set off by dipping the coated bandage in cold water and squeezing several times before application to a mandrel representing a limb.
  • the mixture was stirred at room temperature for 30 minutes before raising the temperature to 70°C, which was maintained for 2 hours, before adding potassium fluoride (20g, 2% w/w). After 24 hours bisphenol A ethoxylated diacrylate (361 g, 3.5 mol) was added and after a further 20 hours acetylchloride (16g, 1.6% w/w) was added dropwise over a period of 20 minutes. The mixture was left stirring for 1 hour before cooling.
  • the prepolymer prepared above had a viscosity of 67,000 mPa s and was coated onto a dry glass fibre bandage by passing the substrate through the prepolymer followed by passing the coated bandage through a nip roller, adjusted to a suitable pressure for obtaining a coating weight of 50-60% w/w.
  • the prepolymer was set off by dipping the coated bandage in cold water and squeezing several times before application to a mandrel representing a limb.
  • A) PolvHEMA coated potassium fluoride Preparation of polyHEMA coated potassium fluoride was carried out by charging a 3L resin flask with 2- hydroxyethylmethacrylate (250g), potassium fluoride (250g, 90 ⁇ m sieved and milled) and dry ethyl acetate (2.5L). The flask was provided with a stirrer, purged thoroughly with nitrogen, and stirred for three hours, followed by addition of bis (4-t-butyl cyclohexyl) peroxydicarbonate (BCHPC, 2% by weight) and stirring for 5Y 2 hours at 55°C.
  • BCHPC bis (4-t-butyl cyclohexyl) peroxydicarbonate
  • the percentage yield was 96%.
  • the mixture was stirred at room temperature for 30 mintues before raising the temperature to 70°C which was maintained for 48- 72 hours, before cooling and adding polyHEMA coated potassium fluoride (13.5g, 4% w/w).
  • the prepolymer prepared above was coated onto a dry glass fibre bandage by passing the substrate through the prepolymer followed by passing the coated bandage through a nip roller, adjusted to a suitable pressure for obtaining a coating weight of 50- 60% w/w.
  • the prepolymer was set off by dipping the coated bandage in cold water and squeezing several times before application to a mandrel representing a limb.
  • Example 8 Methylene bisacrylamide (77.5g, 0.5 mol) and aminopropyl triethoxysilane (222.5g, 1.0 mol) were placed in a 750cm 3 flange flask fitted with a calcium chloride guard tube and an overhead stirrer. The mixture was heated with stirring at 70°C for 48 hours to form a prepolymer.
  • Jeffamine EDR-148 is a polyethylene glycol diamine, obtainable from Huntsman Co ⁇ oration.
  • Cab-o-SilTM is fumed silica obtainable from Cabot Corporation (USA) Potassium fluoride, obtainable from Aldrich Chemical Co.
  • Copper (II) sulphate obtainable from Aldrich Chemical Co.
  • Caesium fluoride obtainable from Aldrich Chemical Co.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention porte sur un bandage orthopédique consistant en un substrat flexible, en un système de prépolymère de silane fonctionnalisé durcissant à l'eau, et en au moins un sel hydrosoluble d'halogénure servant de catalyseur.
PCT/GB1997/001066 1996-04-18 1997-04-17 Materiels orthopediques WO1997038646A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU25726/97A AU2572697A (en) 1996-04-18 1997-04-17 Orthopaedic materials
EP97917345A EP0847282A1 (fr) 1996-04-18 1997-04-17 Materiels orthopediques

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9608004.9A GB9608004D0 (en) 1996-04-18 1996-04-18 Orthopaedic materials
GB9608004.9 1996-04-18
GBGB9615129.5A GB9615129D0 (en) 1996-07-18 1996-07-18 Orthopaedic materials
GB9615129.5 1996-07-18
GBGB9704641.1A GB9704641D0 (en) 1997-03-06 1997-03-06 Orthopaedic materials
GB9704641.1 1997-03-06

Publications (2)

Publication Number Publication Date
WO1997038646A2 true WO1997038646A2 (fr) 1997-10-23
WO1997038646A3 WO1997038646A3 (fr) 1997-11-20

Family

ID=27268249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001066 WO1997038646A2 (fr) 1996-04-18 1997-04-17 Materiels orthopediques

Country Status (3)

Country Link
EP (1) EP0847282A1 (fr)
AU (1) AU2572697A (fr)
WO (1) WO1997038646A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6540704B1 (en) 1998-06-01 2003-04-01 Bsn Medical Gmbh & Co. Kg Orthopedic bandage
US20150050854A1 (en) * 2013-08-19 2015-02-19 Fiber Fix Usa, Llc High temperature rigid repair wrap

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611040A (en) * 1985-06-05 1986-09-09 Ppg Industries, Inc. Fluoride ion as a curing catalyst for silicon-containing resins
US5077249A (en) * 1990-08-31 1991-12-31 Dow Corning Corporation Storage stable heat curable organosiloxane compositions containing a microencapsulated catalyst and method for preparing said catalyst
WO1994023768A1 (fr) * 1993-04-13 1994-10-27 Minnesota Mining And Manufacturing Company Nouvelles bandes et resines pour appareils platres, et procedes
WO1996023531A1 (fr) * 1995-02-03 1996-08-08 Smith & Nephew Plc Materiaux pour platrage et pose d'attelle orthopediques
WO1997003707A1 (fr) * 1995-07-22 1997-02-06 Smith & Nephew Plc Bandages orthopediques
WO1997010275A1 (fr) * 1995-09-13 1997-03-20 Smith & Nephew Plc Compositions durcissables

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611040A (en) * 1985-06-05 1986-09-09 Ppg Industries, Inc. Fluoride ion as a curing catalyst for silicon-containing resins
US5077249A (en) * 1990-08-31 1991-12-31 Dow Corning Corporation Storage stable heat curable organosiloxane compositions containing a microencapsulated catalyst and method for preparing said catalyst
WO1994023768A1 (fr) * 1993-04-13 1994-10-27 Minnesota Mining And Manufacturing Company Nouvelles bandes et resines pour appareils platres, et procedes
WO1996023531A1 (fr) * 1995-02-03 1996-08-08 Smith & Nephew Plc Materiaux pour platrage et pose d'attelle orthopediques
WO1997003707A1 (fr) * 1995-07-22 1997-02-06 Smith & Nephew Plc Bandages orthopediques
WO1997010275A1 (fr) * 1995-09-13 1997-03-20 Smith & Nephew Plc Compositions durcissables

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6540704B1 (en) 1998-06-01 2003-04-01 Bsn Medical Gmbh & Co. Kg Orthopedic bandage
US20150050854A1 (en) * 2013-08-19 2015-02-19 Fiber Fix Usa, Llc High temperature rigid repair wrap

Also Published As

Publication number Publication date
AU2572697A (en) 1997-11-07
EP0847282A1 (fr) 1998-06-17
WO1997038646A3 (fr) 1997-11-20

Similar Documents

Publication Publication Date Title
CA2157777A1 (fr) Nouvelles bandes et resines de coulee; methodes d'obtention
JP5024951B2 (ja) 光硬化型整形外科用固定材
JPS60168460A (ja) 合成樹脂製創傷手当用品
AU699059B2 (en) Orthopaedic casting and splinting materials
EP0094222B1 (fr) Bandages, leurs composants et leur utilisation
AU711469B2 (en) Curable compositions
WO1997038646A2 (fr) Materiels orthopediques
JP2009273875A (ja) 光硬化型整形外科用固定材
WO1997003707A1 (fr) Bandages orthopediques
GB2315688A (en) Orthopaedic splinting material
GB2315687A (en) Orthopaedic splinting material
AU5232698A (en) Adhesives
EP0848619A1 (fr) Bandages orthopediques
GB2315689A (en) Orthopaedic splinting material
US5713835A (en) Orthopaedic material
GB2315690A (en) Orthopaedic splinting material
KR100519433B1 (ko) 정형용 소프트 캐스팅 테이프
KR19990075160A (ko) 캐스팅 테이프

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

WWE Wipo information: entry into national phase

Ref document number: 1997917345

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1997917345

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP

Ref document number: 97536880

Format of ref document f/p: F

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997917345

Country of ref document: EP